A study by the University of Oxford shows that Ozempic (Semaglutide), a weight-loss drug under Novo Nordisk, is associated with a reduced incidence of dementia and a range of other mental illnesses.
According to the app of Wisdom Finance, a study by the University of Oxford shows that Ozempic (Semaglutide), a weight-loss drug under Novo Nordisk (NVO.US), is associated with a reduction in the incidence of dementia and a range of other mental illnesses, which increases people's expectations of the potential benefits of this weight-loss drug.
The study found that after one year of taking Ozempic, patients had a 48% lower risk of developing dementia than those taking sitagliptin (a type of diabetes drug); compared with taking sitagliptin or glipizide, patients' risk of developing cognitive impairment was also reduced. In addition, the study also found that patients taking Ozempic had a 28% lower risk of smoking than those taking glipizide. Moreover, it is worth mentioning that the study did not randomly assign patients to take Ozempic or other drugs, but relied on medical records from over 0.1 million American patients. Researchers used statistical methods to ensure that they made the most accurate comparisons possible. John Wilding, a medical professor at the University of Liverpool, said this means that more research is needed to "determine whether Semaglutide does indeed have benefits for reducing cognitive dysfunction in diabetes patients or affecting smoking rates."
It is worth mentioning that the study did not randomly assign patients to take Ozempic or other drugs, but relied on medical records from over 0.1 million American patients. Researchers used statistical methods to ensure that they made the most accurate comparisons possible. John Wilding, a medical professor at the University of Liverpool, said this means that more research is needed to "determine whether Semaglutide does indeed have benefits for reducing cognitive dysfunction in diabetes patients or affecting smoking rates."
It is reported that this study is one of a series of trials to explore the potential benefits of Semaglutide in addition to controlling diabetes and losing weight. Semaglutide is the main ingredient of Novo Nordisk's weight-loss drugs, Ozempic and Wegovy. Most of the other benefits of taking Semaglutide - for heart, kidney and knee arthritis - are related to weight loss, but scientists are also studying whether the drug can help treat alcoholism by reducing the urge to drink.